Encore Dermatology, Inc. Announces Phase 2 Safety Data Demonstrating Lower Systemic Drug Exposure With Impoyz™ (clobetasol propionate) Cream, 0.025% Compared to Temovate® (clobetasol propionate) Cream, 0.05%
Malvern, PA, November 27, 2018
Encore Dermatology, Inc. today announced the publication of a Phase 2, open-label study in SKIN The Journal of Cutaneous Medicine. Subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temovate® (clobetasol propionate) Cream, 0.05% (56.3 vs 152.5 pg/mL, P=0.014).
Encore Dermatology Inc. Announces the launch of IMPOYZTM (clobetasol propionate) Cream, 0.025%, a newly formulated high-potency topical corticosteroid
Malvern, PA, May 1, 2018
Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.
Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%
Malvern, PA, January 17, 2017
Encore Dermatology Inc., a privately held dermatology
company that specializes in developing and commercializing novel prescription products for improving skin health, announced today the availability of TridesilonTM (desonide) Cream, 0.05%
in a 60g tube. TridesilonTM Cream, 0.05% is a low-potency corticosteroid indicated for the
relief of the inflammatory and pruritic manifestations of corticosteroid-responsive
Encore Dermatology, Inc. Announces Launch of HylatopicPlus® Lotion
Malvern, PA, Oct. 13, 2016
Encore Dermatology, Inc., a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus® Lotion in a convenient 14 oz. bottle with pump dispenser.
Encore Dermatology, Inc., A New Specialty Dermatology Company
Malvern, PA, May 18, 2015
Encore Dermatology, Inc. announced today that it has begun to commercialize HylatopicPlus® and Tetrix®, two highly regarded and established U.S. topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates.